LUCD — Lucid Diagnostics Inc.

Summary of Lucid Diagnostics Inc. (LUCD) Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Test Volume: 3,664 EsoGuard tests conducted in Q4 2025, a 29% increase year-over-year, exceeding the target range of 2,500 to 3,000 tests.
• Revenue: $1.5 million for Q4 2025, reflecting a 24% increase from the previous year.
• Cash Position: $34.7 million at year-end, with an average quarterly cash burn of $11.1 million.
• Operating Expenses: Increased from $44.3 million in 2024 to $48.7 million in 2025, largely due to increased sales and market access staffing.
• Non-GAAP Loss: $44 million for the year, with a non-GAAP net loss per share of $0.10 for Q4 and $0.43 for the year, showing improvement compared to 2024.

2. Strategic Updates and Business Highlights

• Medicare and VA Engagement: Significant progress in securing a contract with the U.S. Department of Veterans Affairs (VA) for EsoGuard, aligning pricing with Medicare rates.
• Clinical Evidence: Positive data from a large real-world study on EsoGuard and EsoCheck, demonstrating high technical success rates and safety.
• Reimbursement Strategy: Ongoing discussions with major payers, including UnitedHealthcare, which has included EsoGuard in its endoscopy guidelines, indicating potential for de facto coverage.
• Sales Strategy: Transitioning sales team focus from event-based testing to engaging with physicians and health systems to drive Medicare volume.

3. Forward Guidance and Outlook

• 2026 Expectations: Anticipation of increased test volume driven by VA engagements and expected Medicare coverage. The company is positioned to capitalize on these developments to drive revenue growth.
• EHR Integration: Plans to enhance electronic health record (EHR) integration to facilitate test ordering and result delivery, which is expected to boost commercial activity.

4. Challenges and Points of Concern

• Pending Medicare Approval: The company is awaiting a draft Local Coverage Determination (LCD) from Medicare, which is critical for revenue recognition. Delays in this process could hinder growth.
• Cash Burn Management: Although cash reserves are adequate, the company is cautious about spending, particularly in the current capital market environment, which may limit aggressive expansion.
• Commercial Payer Dynamics: While there are positive signs with some payers, the need for cost-effectiveness data and the complexity of securing in-network coverage remain challenges.

5. Notable Q&A Insights

• Volume Growth Attribution: The recent increase in test volume is attributed to improved team productivity and engagement with existing accounts rather than significant contributions from the VA.
• Medicare Claims: Medicare claims accounted for approximately 16% of test volume in Q4, up from 10-12% in previous quarters, indicating a strategic shift towards this demographic.
• Sales Rep Productivity: The company is cautious about hiring additional sales reps until Medicare coverage is secured, focusing instead on optimizing current resources and productivity.
• Market Potential: The VA's patient population presents a significant market opportunity, with estimates suggesting 2-3 million veterans could be recommended for testing based on existing guidelines.

Overall, Lucid Diagnostics is positioned for potential growth in 2026, contingent upon securing Medicare coverage and effectively leveraging new contracts with the VA and commercial payers. However, the company must navigate challenges related to reimbursement processes and cash management.